The primary endpoint of ORATORIO was 12-week confirmed disability progression (CDP). At the start of the OLE period, patients continued or were switched from OCR-600 mg. Patients in the OLE phase (ORATORIO trial) who discontinued early and do not have a subsequent visit with EDSS measurement were assigned to the OLE phase (ITT population).

**Extended Controlled Period**
- Patients remaining blinded and continued on treatment as assigned.
- Patients completing ORATORIO could enter an open-label extension (OLE) period following study withdrawal.
- The extended controlled period (ECP) ranged from the clinical cut-off date until the first OLE dose was completed, and was completed when the last patient entered OLE (April 17, 2016).

**Objective**
- To assess the efficacy of switching to OCR therapy on disability progression, confirmed at 6 weeks.
- In the OLE phase of the ORATORIO trial in patients with RRMS, with a follow-up duration of 5.5 years.

**Methods**
- **Please scan QR code for previously presented information, containing:**
  - Duration of patient follow-up, and 12-week and 24-week CDP and CCDP analyses
- **Figure 1. ORATORIO treatment periods**

**Extended Controlled Period**
- The OLE began approximately 7 months after the start of OCR in the ORATORIO trial (Figure 1).
- At the start of OLE, patients continued OCR-600 mg or were switched from PBO to OCR (PRO-OCR).
- Patients receiving OCR in the ECP were re-evaluated every 24 weeks.
- 12 weeks after the first patients entered the OLE (Week 186) and after up to 5.5 years of follow-up.

**Conclusions**
- **Main Period for PBO Patients**
  - Transition from PBO to OCR at week 136 (2 years after the first patients entered the OLE).
  - The proportion of patients in the PBO-OCR and OCR-OCR groups with CDP was 46.7% and 31.1%, respectively (Figure 3).
  - The proportion of patients in the PBO-OCR and OCR-OCR groups with CCDP was 27.0% and 15.8%, and 34.2% vs 22.7%, respectively (Figure 4).
  - The proportion of patients in the PBO-OCR and OCR-OCR groups with CDP-T25TW was 48.7% and 42.7%, and 69.4% vs 52.4% (Figure 4).

**Acknowledgments**
- The authors thank the patients and caregivers for their participation in this trial. This research was conducted by Biogen Idec (except for the data presented at the American Academy of Neurology 2018 Annual Meeting).

**References**